Catalyst Pharmaceuticals, Inc. – Congenital Myasthenic Syndrome

Access Program Information

<p>The primary objective of the study is: &bull; To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is: &bull; To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus</p>